MannKind Corporation Stock News

Metropolitan Life Insurance Co NY lifted its position in MannKind Co. (NASDAQ:MNKD) by 145,008.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,299 shares of the biopharmaceutical companys stock after buying an additional 65,254 shares during the period. Metropolitan []

Equities research analysts predict that MannKind Co. (NASDAQ:MNKD) will report sales of $16.99 million for the current quarter, Zacks reports. Three analysts have made estimates for MannKinds earnings, with the lowest sales estimate coming in at $15.87 million and the highest estimate coming in at $18.20 million. MannKind posted sales of $18.44 million during the []

Several brokerages have updated their recommendations and price targets on shares of MannKind (NASDAQ: MNKD) in the last few weeks: 11/13/2021 – MannKind was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization […]

LPL Financial LLC decreased its position in MannKind Co. (NASDAQ:MNKD) by 31.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 28,026 shares of the biopharmaceutical companys stock after selling 12,758 shares during the period. LPL Financial LLCs holdings in MannKind were worth $153,000 as of its most recent SEC filing. Other large investors []

Wall Street analysts predict that MannKind Co. (NASDAQ:MNKD) will announce earnings of ($0.06) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for MannKinds earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.06). MannKind also posted earnings of ($0.06) per share during the same quarter last []

Equities research analysts expect MannKind Co. (NASDAQ:MNKD) to report $16.99 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for MannKinds earnings. The lowest sales estimate is $15.87 million and the highest is $18.20 million. MannKind posted sales of $18.44 million during the same quarter last year, which suggests a []

Zacks Investment Research upgraded shares of MannKind (NASDAQ:MNKD) from a sell rating to a hold rating in a research report sent to investors on Saturday morning, Zacks.com reports. According to Zacks, Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and []

In the latest trading session, 0.65 million MannKind Corporation (NASDAQ:MNKD) shares changed hands as the companys beta touched 1.80. With the companys most recent per share price at $4.82 changed hands at -$0.17 or -3.41% at last look, the market valuation stands at $1.25B. MNKDs current price is a discount, trading about -29.67% off its Could MannKind Corporation (NASDAQ: MNKD) Post Life-Changing Returns? Read More »

Millennium Management LLC cut its holdings in MannKind Co. (NASDAQ:MNKD) by 13.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,490,785 shares of the biopharmaceutical companys stock after selling 386,902 shares during the period. Millennium Management LLCs holdings in []

MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2021 Results - Earnings Call Transcript

MannKind (NASDAQ:MNKD) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to d

Investors are hyperventilating after a delay for its inhaled medicine.

MannKind (MNKD) stock is taking a beating on Monday after releasing an update to investors concerning news from the FDA for Tyvaso DPI. The post MNKD Stock: The Disappointing FDA News That Has MannKin